Tanya M Ellman1, Kellie Hawkins2, Jorge Benitez3, Ramon Negron3, Steven Chang3, Steven Palmer3, Verna Robertson3, Mary Ann Chiasson4, Magdalena E Sobieszczyk3. 1. Division of Infectious Diseases, Department of Medicine, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA; ICAP, Columbia University, Mailman School of Public Health, 722 West 168th Street, Box 18, New York, NY 10032, USA. Electronic address: tme2108@columbia.edu. 2. Department of Medicine, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA; Division of Infectious Diseases, Department of Medicine, University of Colorado, 12700 E. 19th Avenue, Mail Stop B168, Aurora, CO 80045, USA. Electronic address: kellie.hawkins@ucdenver.edu. 3. Division of Infectious Diseases, Department of Medicine, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. 4. Public Health Solutions, 40 Worth Street, 5th Floor, New York, NY 10013, USA; Department of Epidemiology, Columbia University, Mailman School of Public Health, 722 West 168th Street, New York, NY 10032, USA.
Abstract
INTRODUCTION: In the United States, Latinos and Blacks are disproportionately affected by HIV/AIDS, but have been underrepresented in HIV vaccine trials. We assessed screening and enrollment of Blacks and Latinos for preventive HIV vaccine trials conducted in New York City, 2009-2012. METHODS: A retrospective analysis was conducted among 18-50 year old men and transgender women screening for four preventive phase 1 and 2 HIV vaccine trials. Demographic, recruitment, and behavioral/medical eligibility data and outcome of screening were examined. To determine factors associated with enrollment, a multivariable logistic regression analysis was performed. RESULTS: Among 6077 individuals who provided contact information, 2536 completed a phone pre-screen. 96 (1.6% of recruitment contacts) enrolled. Latinos were 35.7% of recruitment contacts, but 17.7% of those enrolled, whereas Blacks were 22.5% and 32.3%, respectively. Among all Latinos, nearly one third were excluded for being uncircumcised, an eligibility criterion for several studies. In multivariable analysis among potentially eligible potential participants, controlling for age and recruitment method, Latinos were less likely than Whites to enroll in a preventive HIV vaccine trial (aOR 0.52, 95% CI 0.28-0.95) whereas Blacks were as likely as Whites (aOR 0.99, 95% CI 0.59-1.67). Individuals recruited through print advertisements, social media/internet, referral, and other modes were more likely to enroll compared to those recruited through in-person outreach, controlling for age and race/ethnicity. CONCLUSIONS: Targeted outreach has led to substantial inclusion of Latinos and Blacks, with Blacks comprising almost a third of those enrolled in these preventive HIV vaccine trials. Latinos, however, were less likely to enroll compared to Whites. Circumcision status as an eligibility criterion partly accounts for this, but further studies are warranted to address the reasons Latinos decide not to participate in preventive HIV vaccine trials.
INTRODUCTION: In the United States, Latinos and Blacks are disproportionately affected by HIV/AIDS, but have been underrepresented in HIV vaccine trials. We assessed screening and enrollment of Blacks and Latinos for preventive HIV vaccine trials conducted in New York City, 2009-2012. METHODS: A retrospective analysis was conducted among 18-50 year old men and transgender women screening for four preventive phase 1 and 2 HIV vaccine trials. Demographic, recruitment, and behavioral/medical eligibility data and outcome of screening were examined. To determine factors associated with enrollment, a multivariable logistic regression analysis was performed. RESULTS: Among 6077 individuals who provided contact information, 2536 completed a phone pre-screen. 96 (1.6% of recruitment contacts) enrolled. Latinos were 35.7% of recruitment contacts, but 17.7% of those enrolled, whereas Blacks were 22.5% and 32.3%, respectively. Among all Latinos, nearly one third were excluded for being uncircumcised, an eligibility criterion for several studies. In multivariable analysis among potentially eligible potential participants, controlling for age and recruitment method, Latinos were less likely than Whites to enroll in a preventive HIV vaccine trial (aOR 0.52, 95% CI 0.28-0.95) whereas Blacks were as likely as Whites (aOR 0.99, 95% CI 0.59-1.67). Individuals recruited through print advertisements, social media/internet, referral, and other modes were more likely to enroll compared to those recruited through in-person outreach, controlling for age and race/ethnicity. CONCLUSIONS: Targeted outreach has led to substantial inclusion of Latinos and Blacks, with Blacks comprising almost a third of those enrolled in these preventive HIV vaccine trials. Latinos, however, were less likely to enroll compared to Whites. Circumcision status as an eligibility criterion partly accounts for this, but further studies are warranted to address the reasons Latinos decide not to participate in preventive HIV vaccine trials.
Authors: Amina P Alio; Sheldon D Fields; Damon L Humes; Catherine A Bunce; Stephaun E Wallace; Cindi Lewis; Heather Elder; Steven Wakefield; Michael C Keefer Journal: J Gay Lesbian Soc Serv Date: 2014-07-01
Authors: Mary A Allen; Thomas S Liang; Thomas La Salvia; Brian Tjugum; Robert J Gulakowski; Matthew Murguía Journal: J Acquir Immune Defic Syndr Date: 2005-12-15 Impact factor: 3.731
Authors: David C Montefiori; Barbara Metch; M Juliana McElrath; Steve Self; Kent J Weinhold; Lawrence Corey Journal: J Infect Dis Date: 2004-10-28 Impact factor: 5.226
Authors: Gaston Djomand; Joanna Katzman; Dante di Tommaso; Michael G Hudgens; George W Counts; Beryl A Koblin; Patrick S Sullivan Journal: Public Health Rep Date: 2005 Sep-Oct Impact factor: 2.792
Authors: Paula M Frew; Carlos del Rio; Lu Lu; Sarah Clifton; Mark J Mulligan Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: Jennifer Freytag; Zhixin J Jiang; Thomas P Giordano; Robert A Westbrook; Sheryl A McCurdy; Sarah Njue-Marendes; Bich N Dang Journal: Patient Educ Couns Date: 2019-03-25